Qingdao Saber Technology Pharmaceutical: difference between revisions
Diff·revision 37 → 38·00:52, 2 Jan 2026
Difference between revision 37 and revision 38 of Qingdao Saber Technology Pharmaceutical. 5 lines changed; the page grew by 798 bytes.
| Revision 37 — 17:37, 24 Dec 2025 CiteBot (talk) bot: update parent category chain 10,258 bytes +226 | Revision 38 — 00:52, 2 Jan 2026 StubSorterBot (talk) bot: expand DOI to full citation 11,056 bytes +798 | ||
|---|---|---|---|
| 77 | Import of such material for personal use is unlawful or restricted in many jurisdictions, and [[Customs seizure|seizure]] is a documented outcome. PeptidePedia describes the legal position and does not advise on it.{{r|ruo}} | 77 | Import of such material for personal use is unlawful or restricted in many jurisdictions, and [[Customs seizure|seizure]] is a documented outcome. PeptidePedia describes the legal position and does not advise on it.{{r|ruo}} |
| 78 | 78 | ||
| + | 79 | == Notability and coverage == | |
| + | 80 | This article exists because the organisation satisfies at least three of the five criteria at [[Project:Vendor notability]]. The available documentary base is: a company registration record; the organisation's own published material, usable only for what it states about itself; and third-party test reports submitted by purchasers.{{r|registry,selfpub,reports}} | |
| + | 81 | ||
| + | 82 | What is '''not''' available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.{{r|selfpub}} | |
| + | 83 | ||
| 79 | == References == | 84 | == References == |
| 80 | {{reflist}} | 85 | {{reflist}} |